Skip to main content

Table 1 Demographic and clinical characteristics of prostate cancer patients in UK Biobank

From: Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes

Characteristics

Lethal PCa

Non-lethal PCa

All

P valueb

Male participants, No. (%)

959 (6.6)

13,590 (93.4)

14,549

 

Age at diagnostic, mean (SD), yr

65.8 (6.2)

66.9 (6.5)

66.9 (6.5)

0.013

Age at death, mean (SD), yr

71.6 (5.3)

73.5 (5.1)a

72.7 (5.3)

 < 0.001

BPH diagnosis, No. (%)

   

0.004

 Yes

151 (15.7)

2657 (19.6)

2808 (19.3)

 

 No

808 (84.3)

10,933 (80.4)

11,741 (80.7)

 

Family history of PCa, No. (%)

   

0.949

 Yes

114 (11.9)

1617 (11.9)

1731 (11.9)

 

 No

799 (83.3)

11,402 (83.9)

12,201 (83.9)

 

 Missing

46 (4.8)

571 (4.2)

617 (4.2)

 

Charlson comorbidity index scores

   

 < 0.001

 0

108 (11.3)

4441 (32.7)

4549 (31.3)

 

 1–2

112 (11.7)

5906 (43.4)

6018 (41.4)

 

  > 2

739 (77.0)

3243 (23.9)

3982 (27.3)

 

Genetic kinship

   

0.098

 No kinship found

644 (67.2)

9447 (69.5)

10,091 (69.3)

 

 At least one relative identified

314 (32.7)

4136 (30.4)

4450 (30.6)

 

 Ten or more third-degree relatives

1 (0.1)

7 (0.1)

8 (0.1)

 

WES data, No. (%)

392 (40.9)

5504 (40.5)

5896 (40.5)

0.808

  1. PCa, Prostate cancer; BPH, Benign prostate hyperplasia; N/A, Not applicable; WES, Whole-exome sequencing
  2. a1173 deaths due to other reasons, not for PCa as primary death cause
  3. bChi-squared test or t test was used to compare lethal PCa group and Non-lethal PCa group